Chiasma Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Chiasma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CHMA, but not buy additional shares or sell existing shares.
View analyst ratings for Chiasma or view top-rated stocks.

Wall Street analysts have given Chiasma a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chiasma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Chiasma saw a drop in short interest during the month of May. As of May 28th, there was short interest totaling 2,760,000 shares, a drop of 39.3% from the May 13th total of 4,550,000 shares. Based on an average daily volume of 3,060,000 shares, the days-to-cover ratio is currently 0.9 days. Currently, 5.6% of the company's shares are sold short.
View Chiasma's Short Interest.

Chiasma is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Chiasma.

Chiasma, Inc. (NASDAQ:CHMA) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.18. The biotechnology company earned $1.92 million during the quarter, compared to analyst estimates of $1.80 million.
View Chiasma's earnings history.

Chiasma's stock was trading at $3.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CHMA stock has increased by 7.4% and is now trading at $4.21.
View which stocks have been most impacted by COVID-19.

3 brokerages have issued 12-month price targets for Chiasma's stock. Their forecasts range from $8.00 to $15.00. On average, they anticipate Chiasma's share price to reach $11.67 in the next twelve months. This suggests a possible upside of 177.1% from the stock's current price.
View analysts' price targets for Chiasma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Chiasma include Amphastar Pharmaceuticals (AMPH), Travere Therapeutics (TVTX), Mersana Therapeutics (MRSN), Aclaris Therapeutics (ACRS), ChemoCentryx (CCXI), Omeros (OMER), BioXcel Therapeutics (BTAI), Syndax Pharmaceuticals (SNDX), Gracell Biotechnologies (GRCL), Enanta Pharmaceuticals (ENTA), Arcturus Therapeutics (ARCT), ESSA Pharma (EPIX), Annexon (ANNX), G1 Therapeutics (GTHX) and Evelo Biosciences (EVLO).
View all of CHMA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals (GWPH), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Amarin (AMRN), Exelixis (EXEL) and Ovid Therapeutics (OVID).

(CHMA) raised $76 million in an IPO on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Chiasma's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.45%), Rock Springs Capital Management LP (3.76%), Geode Capital Management LLC (1.44%), Ikarian Capital LLC (1.05%), Northern Trust Corp (0.88%) and Dimensional Fund Advisors LP (0.44%). Company insiders that own Chiasma stock include David M Stack, Raj Kannan, Roni Mamluk, Scott Minick and William Ludlam.
View institutional ownership trends for Chiasma.

CHMA stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, The Manufacturers Life Insurance Company, Man Group plc, Ikarian Capital LLC, Northern Trust Corp, Nuveen Asset Management LLC, Squarepoint Ops LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Chiasma or view top insider-selling stocks.

CHMA stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Geode Capital Management LLC, BlackRock Inc., JPMorgan Chase & Co., Jane Street Group LLC, Rock Springs Capital Management LP, PDT Partners LLC, and Arrowstreet Capital Limited Partnership. Company insiders that have bought Chiasma stock in the last two years include David M Stack, Raj Kannan, Scott Minick, and William Ludlam.
View insider buying and selling activity for Chiasma or or view top insider-buying stocks.

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHMA stock can currently be purchased for approximately $4.21.

Chiasma has a market capitalization of $243.73 million and generates $1.11 million in revenue each year. The biotechnology company earns $-74,780,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

Chiasma employs 84 workers across the globe.

The official website for Chiasma is www.chiasmapharma.com.

Chiasma is headquartered at 140 Kendrick Street Building C East, Needham MA, 02494.

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]